Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | DUT | P33316 | 8/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2983407 | 0.83 | ALDH1A1 (0.57) | ALDH1A1LMNAPKMCRBNL3MBTL1 | |
| SCHEMBL10924758 | 0.82 | PKM (0.55) | ALDH1A1LMNAPKMCRBNL3MBTL1 | |
| SCHEMBL4348697 | 0.82 | L3MBTL1 (0.59) | ALDH1A1LMNAPKMCRBNL3MBTL1 | |
| SCHEMBL4347791 | 0.81 | ALDH1A1 (0.50) | ALDH1A1LMNAPKMCRBNL3MBTL1 | |
| SCHEMBL3079985 | 0.80 | DUT (0.56) | ALDH1A1LMNACRBNL3MBTL1DUT | |
| SCHEMBL6102943 | 0.80 | CRBN (0.56) | ALDH1A1LMNAPKMCRBNL3MBTL1 | |
| SCHEMBL5180752 | 0.79 | ALDH1A1 (0.49) | ALDH1A1LMNAPKMCRBNL3MBTL1 | |
| SCHEMBL913206 | 0.79 | DUT (0.55) | ALDH1A1LMNAL3MBTL1DUT | |
| SCHEMBL254514 | 0.79 | DUT (0.56) | ALDH1A1LMNAPKML3MBTL1DUT | |
| SCHEMBL8377765 | 0.78 | PKM (0.51) | ALDH1A1LMNAPKMCRBNL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 500 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137486-A1 | CAP COMPOUNDS AND RNAS COMPRISING THE SAME | HELIX NANOTECHNOLOGIES INC (US) | 2025-06-26 | — | — | WO | claimed |
| US-20250206770-A1 | CAP COMPOUNDS AND RNAS COMPRISING THE SAME | HELIX NANOTECHNOLOGIES INC | 2025-06-26 | — | — | US | claimed |
| EP-4337331-A1 | MODIFIED MRNA, MODIFIED NON-CODING RNA, AND USES THEREOF | The Broad Institute Inc. (US) | 2024-03-20 | — | — | EP | claimed |
| EP-4314332-A2 | METHODS FOR IDENTIFICATION AND RATIO DETERMINATION OF RNA SPECIES IN MULTIVALENT RNA COMPOSITIONS | ModernaTX, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| CN-109804083-B | Single primer to double primer amplicon conversion | 西格马-奥尔德里奇有限责任公司 | 2023-11-03 | — | — | CN | claimed |
| EP-4133111-A1 | DEVICE AND METHOD FOR PHOTOTHERMAL ENHANCED PLASMONIC BIOSENSING | EMPA Eidgenössische Materialprüfungs- und Forschungsanstalt (CH) | 2023-02-15 | — | — | EP | claimed |
| US-20220315972-A1 | SINGLE PRIMER TO DUAL PRIMER AMPLICON SWITCHING | SIGMA ALDRICH CO LLC (US) | 2022-10-06 | — | — | US | claimed |
| US-11400042-B2 | Process for treating keratin fibres, comprising the application of a composition comprising urea or a derivative thereof, a polyol and an amino silicone | L'OREAL (FR) | 2022-08-02 | — | — | US | claimed |
| US-11390913-B2 | Single primer to dual primer amplicon switching | SIGMA-ALDRICH CO. LLC (US) | 2022-07-19 | — | — | US | claimed |
| US-11298305-B2 | Compositions and methods for improving the appearance of the hair | L'OREAL (FR) | 2022-04-12 | — | — | US | claimed |
| WO-2016183100-A1 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID AMPLIFICATION | Twist Bioscience Corporation (US) | 2016-11-17 | — | — | WO | claimed |
| US-20150093752-A1 | Conversion of alpha-hydroxyalkylated residues in biomolecules using methyltransferases | VILNIUS UNIVERSITY (LT) | 2015-04-02 | — | — | US | claimed |
| WO-2008033432-A2 | IMMUNE MODULATION BY CHEMICALLY MODIFIED RIBONUCLEOSIDES AND OLIGORIBONUCLEOTIDES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-03-20 | — | — | WO | claimed |
| EP-1282639-A2 | POLYAMIDE NUCLEIC ACID DERIVATIVES, AGENTS AND METHODS FOR PRODUCING THE SAME | Aventis Pharma Deutschland GmbH (DE) | 2003-02-12 | — | — | EP | claimed |
| WO-2001079249-A2 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH A NEGATIVE CHARGE, AGENTS AND METHODS FOR PRODUCING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-10-25 | — | — | WO | claimed |
| WO-2001068807-A2 | IDENTIFICATION OF IN VIVO DNA BINDING LOCI OF CHROMATIN PROTEINS USING A TETHERED NUCLEOTIDE MODIFICATION ENZYME | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2001-09-20 | — | — | WO | claimed |
| EP-0934521-A1 | IN VITRO ASSAY FOR CARCINOGENS USING PHENOTYPIC TRANSFORMATION OF HUMAN CELLS | Viratest Carcinogen Monitoring, Ltd. (CA) | 1999-08-11 | — | — | EP | claimed |
| US-5763180-A | In vitro assay for carcinogens using phenotypic transformation of human cells | VIRATEST CARCINOGEN MONITORING LTD. (CA) | 1998-06-09 | — | — | US | claimed |
| WO-1998007030-A1 | IN VITRO ASSAY FOR CARCINOGENS USING PHENOTYPIC TRANSFORMATION OF HUMAN CELLS | VIRATEST CARCINOGEN MONITORING LTD. (US) | 1998-02-19 | — | — | WO | claimed |
| WO-1993017651-A2 | ANTIVIRAL NUCLEOSIDE ANALOGUES, THEIR PRODUCTION AND USE | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 1993-09-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11298305-B2 | Compositions and methods for improving the appearance of the hair | KRT18, OAT, CKMT1A; CKMT1B | ALDH1A1 2800/4885LMNA 1081/4885PKM 889/4885 |
| US-20250206770-A1 | CAP COMPOUNDS AND RNAS COMPRISING THE SAME | RNGTT, RNMT, NSUN2 | ALDH1A1 1939/4885LMNA 828/4885PKM 4358/4885 |
| US-11400042-B2 | Process for treating keratin fibres, comprising the application of a composition comprising urea or a derivative thereof, a polyol and an amino silicone | KRT18, CUTA, PUF60 | ALDH1A1 3876/4885LMNA 477/4885PKM 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.